Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00038051
Status:
COMPLETED
Last Update Posted:
2013-04-04
First Post:
2002-05-24
Brief Title:
Evaluation of the Anti-CD-33 Immunotoxin Hum-195rGel in Patients With Advanced Myeloid Malignancies
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
Phase I Evaluation of the Anti-CD-33 Immunotoxin Hum-195rGel in Patients With Advanced Myeloid Malignancies
Status:
COMPLETED
Status Verified Date:
2013-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical research study is to find the highest safe dose of the anti-CD33 immunotoxin HuM-195rGel that can be given to patients with advanced myeloid malignancies This treatment will be given to patients whose leukemia has not responded to prior chemotherapy
Detailed Description:
Before therapy all patients will be asked about their medical history and a physical exam with measurement of vital signs will be performed A chest X-ray and an electrocardiogram ECG - a test to measure the electrical activity of the heart will be performed Blood about 4 teaspoons will be drawn for routine tests and blood clotting tests Women who are able to become pregnant will have a urine pregnancy test done A test will be done to measure the amount of oxygen in your blood by placing a monitoring device on your finger Blood about 1 teaspoon will be taken to measure the amount of a protein that is present on the diseased cells During the study period the study staff will draw blood samples for routine tests pharmacokinetic PK tests and anti-drug antibody tests Blood about 1 teaspoon will be drawn to measure the amount of a protein that is present on the diseased cells A bone marrow sample will also be obtained before treatment and on Study Day 28
Patients will receive four injections of the immunotoxin The immunotoxin is designed to selectively destroy myeloid leukemia cells The injections will be given through a vein twice weekly for two weeks Patients will then be evaluated twice weekly for the next two weeks If there has been improvement in the leukemia or if the leukemia has remained stable and there have been no serious side effects of treatment patients will then receive a second course of immunotoxin injections These will again be given twice weekly for two weeks Depending on the effectiveness against leukemia and the side effects patients may receive maintenance treatment This would also consist of two weekly injections given for two weeks followed by two weeks of observation Maintenance therapy may continue for up to four months for partial response and up to two months for complete response
This is an investigational study Up to 36 patients will take part in this study
Patients will receive four injections of the immunotoxin The immunotoxin is designed to selectively destroy myeloid leukemia cells The injections will be given through a vein twice weekly for two weeks Patients will then be evaluated twice weekly for the next two weeks If there has been improvement in the leukemia or if the leukemia has remained stable and there have been no serious side effects of treatment patients will then receive a second course of immunotoxin injections These will again be given twice weekly for two weeks Depending on the effectiveness against leukemia and the side effects patients may receive maintenance treatment This would also consist of two weekly injections given for two weeks followed by two weeks of observation Maintenance therapy may continue for up to four months for partial response and up to two months for complete response
This is an investigational study Up to 36 patients will take part in this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None